Related Experiment Videos
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management
1Department of Medicine, J.W. Goethe University, Frankfurt, Germany.
The American Journal of Cardiology
|November 14, 1997
Summary
Antiarrhythmic drugs can cause proarrhythmia, particularly Torsades de Pointes, by affecting cardiac repolarization. Amiodarone shows lower risk, while pure class III agents like d-sotalol warrant careful use due to mortality concerns.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Antiarrhythmic drugs exert proarrhythmic effects by altering cardiac electrophysiology.
- Torsades de Pointes (TdP) is a classic proarrhythmic reaction linked to repolarization prolongation, common with Class III agents.
Purpose of the Study:
- To review the proarrhythmic potential of antiarrhythmic drugs, focusing on Class III agents and Torsades de Pointes.
- To discuss the electrophysiologic mechanisms and clinical implications of drug-induced proarrhythmia.
Main Methods:
- Review of existing literature on antiarrhythmic drug effects and proarrhythmia.
- Analysis of clinical trial data, including the Survival With Oral d-Sotalol (SWORD) trial.
Main Results:
- Class III agents prolong repolarization, increasing TdP risk; amiodarone has a lower risk due to its complex profile.
- D,l-sotalol's TdP incidence correlates with dose and baseline QT interval.
- The SWORD trial indicated increased mortality with d-sotalol in post-infarction patients, suggesting a potential class effect for pure Class III drugs.
Conclusions:
- Careful patient selection and monitoring are crucial when using Class III antiarrhythmic drugs.
- Management of drug-induced TdP involves drug cessation, correcting predisposing factors, and potentially magnesium sulfate or pacing.